热门资讯> 正文
SpringWorks治疗公司宣布米达米尼治疗NF1-PN的2b期ReNeu试验的Topline结果
2023-11-16 19:33
- Confirmed objective response rate of 52% in pediatric patients and 41% in adult patients, as assessed by Blinded Independent Central Review
- Mirdametinib treatment resulted in deep and durable responses and significant improvements in key secondary patient-reported outcome measures –
- Mirdametinib was generally well tolerated with low rates of Grade 3+ adverse events –
- Additional data expected to be presented at medical conference and NDA submission to the U.S. FDA planned in the first half of 2024 –
- Company to host conference call today at 8:30 a.m. Eastern Time –
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
